共 110 条
- [1] Squadroni M(2010)Chemotherapy in pancreatic adenocarcinoma Eur Rev Med Pharmacol Sci. 14 386-3894
- [2] Fazio N(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol. 15 2403-13
- [3] Burris HA(1996)A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer Ann Oncol. 7 347-53
- [4] Moore MJ(1999)Current chemotherapeutic possibilities in pancreaticobiliary cancer Ann Oncol. 10 S157-61
- [5] Anderson J(1999)Experimental drugs and drug combinations in pancreatic cancer Ann Oncol. 10 S234-8
- [6] Rothenberg ML(2003)Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death Oncogene. 22 3243-51
- [7] Moore MJ(2006)Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma Ann Surg Oncol 13 933-9
- [8] Cripps MC(2013)ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells J Int Med Res. 41 300-6
- [9] van Riel JMGH(2010)The biochemistry of apoptosis Nature. 407 770-6
- [10] van Groeningen CJ(2000)Role of the BH3 (bcl-2 homology 3) domain in the regulation of apoptosis and bcl-2-related proteins Biochem Soc Trans. 28 51-6